Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04750265
Other study ID # ROBEM II
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 29, 2021
Est. completion date February 3, 2022

Study information

Verified date August 2023
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Feasibility trial investigating the potential higher frequency of robotic assisted early mobilization in intubated COVID19 patients on the ICU.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date February 3, 2022
Est. primary completion date August 8, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Age = 18 years - Invasive mechanically ventilated and expected to be ventilated for another 24 hours - Cardiovascular stability, allowing mobilization - Respiratory stability, allowing mobilization Exclusion Criteria: - Bed-bound before ICU admission - Bed-rest order or contraindication of weight load of the lower extremity or spine - Severe skin lesions or fasciitis in the area of contact with the device or rhabdomyolysis - Fresh SAB, ICB or elevated ICP - Status epilepticus - Acute intoxication - Shock with catecholamine doses >0.3µg/kg/min or acute bleeding including organ ruptures - Multiorgan failure with lactate > 4 mmol/l - Body height outside the range 150-195 cm - Body weight outside the range 45-135 kg - pAVK IV° - Pacemakers or other electrical stimulators - Implanted medical pumps - Pregnancy - Life expectancy below 7 days or acute palliative care situation - Death inevitable or maximum therapy is not carried out by the treating physicians or due to patient's request - Unable to understand the official language

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Robotic assisted early mobilization
Robotic assisted early mobilization Robotic assisted early mobilization started within 72 hours of ICU admission.

Locations

Country Name City State
Germany Charité - Univiversitätsmedizin Berlin Berlin-Mitte Berlin

Sponsors (2)

Lead Sponsor Collaborator
Charite University, Berlin, Germany Reactive Robotics GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Level of mobilization Level of mobilization during the first 5 days after admission on the ICU, measured with the ICU-Mobility Scale (0-10) 5 days
Primary Level of mobilization Level of mobilization during the first 5 days after admission on the ICU, measured with the Surgical Optimal Mobilization Scale (0-4) 5 days
Secondary Frequency of Mobilization Frequency of early mobilization during mechanical ventilation 5 days
Secondary Initiation of first Mobilization Time of first mobilization after admission on ICU (in hours) 5 days
Secondary Mobilization duration Average duration of mobilization sessions during mechanical ventilation (in min) 5 days
Secondary Depth of sedation Depth of sedation measured with RASS during the first 5 days after admission on ICU 5 days
Secondary Days of sedation Days under sedative medication during ICU stay during ICU stay (normally up to 30 days)
Secondary Days of mechanical ventilation Days of mechanical ventilation during ICU stay during ICU stay (normally up to 30 days)
Secondary Days of Intubation Days of Intubation during ICU stay during ICU stay (normally up to 30 days)
Secondary Days of Delirium Days of Delirium during ICU stay during ICU stay (normally up to 30 days)
Secondary MRC Score MRC Score at ICU Discharge One time point before ICU Discharge
Secondary Muscle wasting Muscle wasting assessed using ultrasound measurement of the M. femoris 5 days
Secondary Number of Health care provider Number of Health care provider needed for mobilization 5 days
Secondary Mortality Mortality during ICU and Hospital stay and 180 days after admission at ICU at 180 days after study start
Secondary Length of stay Length of stay at ICU , in Hospital (in days) Hospital stay (approx. 30 days)
Secondary Global function Global function measured with WHODAS at 180 days after study start
Secondary Health care provider assessment Assessment of the satisfaction with the mobilization by the health care provider using Likert-Scales (1-5) 5 days
Secondary Safety events Frequency of safety events during mobilization 5 days after study start
Secondary Functional status Measurement of ADLs/IADLs for which patients need assistance at 180 days after study start
Secondary DRG workplace data expenses of the hospital stay Hospital stay (approx. 30 days)
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3